Search Results
Feb 25, 2026, 07:45 ET Singular Genomics at AGBT 2026: Population-Scale Spatial Takes Center Stage G4X Launch, SPOT-Met Initiative
multimodal spatial initiative, was featured in an AGBT 2026 conference presentation.Expanded content: Showcased 1,300-gene plex RNA panel on G4X, increasing platform capability beyond 500 genes, while enabling simultaneous assessment of 18 proteins and fH&E.Direct-Seq
More news about: Singular Genomics
Feb 25, 2026, 03:24 ET Frontier Biotech und GSK schließen globale Exklusivlizenzvereinbarung für therapeutische Anwendungen mit kleinen interferierenden RNAs
Exklusivrechte für die Entwicklung, Herstellung und Vermarktung von zwei Produkten aus der Pipeline von Frontier Biotech im Bereich Small Interfering RNA (siRNA), von denen sich eines derzeit in der Phase der Zulassung als neues Prüfpräparat (Investigational New Drug, IND) befindet und das andere ein präklinischer
More news about: Frontier Biotechnologies Inc.
Feb 25, 2026, 03:00 ET ARTHEx Biotech Announces Publication in The American Journal of Human Genetics Highlighting the Discovery and Preliminary Preclinical Profile of ATX-01 for Myotonic Dystrophy Type 1 (DM1)
thank Cell Press for recognizing this important preclinical work."DM1 is a multisystemic, RNA-mediated genetic disorder caused by expanded CTG repeats in the DMPK gene, leading to toxic RNA transcripts that disrupt post-transcriptional regulation. A central pathogenic mechanism is the depletion
More news about: ARTHEx Biotech
Feb 24, 2026, 20:30 ET Frontier Biotech et GSK concluent un accord de licence exclusif à l'échelle mondiale pour les thérapies fondées sur les petits ARN interférents (siRNA)
de l'accord, GSK obtiendra les droits exclusifs mondiaux pour développer, fabriquer et commercialiser deux des produits du pipeline Small Interfering RNA (siRNA) de Frontier Biotech, dont l'un est actuellement au stade d'Investigational New Drug (IND) et l'autre au stade de candidat préclinique. Cet
More news about: Frontier Biotechnologies Inc.
Feb 24, 2026, 13:30 ET Direct Genome-Scale Mapping of Endonuclease Activity of the Human LINE-1 ORF2p Endonuclease
retrotransposon that causes DNA damage and mutagenizes the human genome.LINE-1 is an autonomous retrotransposon that expands within the genome through an RNA-mediated "copy and paste" mechanism and has written around one-third of the human genome. Approximately 5% of humans harbor a new LINE-1–mediated genomic
More news about: Nabsys
Feb 24, 2026, 10:08 ET Cellipont Bioservices and Soter Bio Announce Strategic Collaboration to Support Integrated U.S. Cell Therapy Manufacturing
platforms that span RNA production through cell processing. Recent activity across the RNA ecosystem, including platform integrations and strategic partnerships by companies such as Quantoom Biosciences—highlights increasing demand for coordinated manufacturing solutions supporting RNA-based and cell therapy
More news about: Cellipont Bioservices
Feb 24, 2026, 08:30 ET Therna Biosciences Appoints Biotech Veteran Devyn Smith, Ph.D., to Board of Directors and Expands Strategic and Scientific Advisory Leadership
University of Pennsylvania and a specialist in RNA delivery technologies. Her research focuses on RNA therapeutics and advanced drug delivery systems. She leads work on developing and optimizing delivery technologies critical to the safe and effective distribution of RNA-based medicines. Dr. Parhiz was a scientific
More news about: Therna Biosciences
Feb 24, 2026, 06:02 ET Frontier Biotech and GSK Enter Global Exclusive Licensing Agreement for Small Interfering RNA Therapeutics
of the agreement, GSK will obtain exclusive worldwide rights to develop, manufacture, and commercialize two of Frontier Biotech's Small Interfering RNA (siRNA) pipeline products, one of which is currently at Investigational New Drug (IND) stage and the other is a preclinical candidate. This agreement
More news about: Frontier Biotechnologies Inc.
Feb 24, 2026, 05:55 ET Frontier Biotech and GSK Enter Global Exclusive Licensing Agreement for Small Interfering RNA Therapeutics
of the agreement, GSK will obtain exclusive worldwide rights to develop, manufacture, and commercialize two of Frontier Biotech's Small Interfering RNA (siRNA) pipeline products, one of which is currently at Investigational New Drug (IND) stage and the other is a preclinical candidate. This agreement
More news about: Frontier Biotechnologies Inc.
Feb 24, 2026, 02:00 ET etherna's intratumoral mRNA/LNP platform advances to clinical testing in nonmelanoma skin cancer led by Almirall
proprietary platforms, including customizable lipid nanoparticles (cLNPs) and advanced mRNA chemistry to enable the delivery of differentiated and efficacious RNA therapeutics. Founded in 2013 as a spin-off from the Vrije Universiteit Brussel (VUB), etherna has evolved from a developer of immunotherapies into a
More news about: etherna
Feb 23, 2026, 12:00 ET New Gentle Methyl Conversion Kit Delivers High-Accuracy Profiling from as Little as 100 pg of DNA
developers to capture the full complexity of the DNA and RNA landscape. Spun out of The University of Chicago and boasting Scientific Founder Professor Chuan He, Ellis Bio's portfolio goes beyond sequencing to provide insights into the DNA and RNA modifications that drive gene expression, collectively
More news about: Ellis Bio Inc
Feb 23, 2026, 08:01 ET TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development
Feb. 23, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, today announced the publication of a manuscript titled Template-Directed RIG-I Agonist
More news about: TransCode Therapeutics, Inc.
Feb 23, 2026, 08:00 ET Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
Feb. 23, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ("AOCs™") to profoundly improve people's lives, today announced
More news about: Avidity Biosciences, Inc.
Feb 20, 2026, 10:00 ET New England Biolabs® to present latest updates in Next Generation Sequencing Sample Preparation at 2026 AGBT Meeting
NEBNext Low-bias Small RNA Library Prep Kit. The kit features a single-day, gel-free workflow, based on a proprietary approach for unbiased ligation of sequencing adaptors to enable sequencing across the range of miRNA and small RNA applications.NEB will be presenting two
More news about: New England Biolabs, Inc.
Feb 20, 2026, 08:00 ET Zenocutuzumab Treatment Beyond Progression Demonstrates Continued Benefit in Patients with NRG1+ Non-Small Cell Lung Cancer: New Results from the eNRGy Trial
benefit in a confirmatory trial(s). NRG1 gene fusions and other gene fusions are best detected using the combination of tissue-based DNA and RNA next-generation sequencing.For more information on the eNRGy trial and zenocutuzumab-zbco, please visit
More news about: Partner Therapeutics, Inc.
Feb 19, 2026, 08:00 ET Stellaromics Launches Pyxa™ at AGBT, the First Commercial Platform for 3D Spatial Multi-Omics in Intact Tissue
Human Cell Atlas initiative.Emory University School of Medicine: Dr. Hailing Shi's group is deploying Pyxa to study RNA regulation and molecular organization in neural tissue.Improvements based on feedback from beta partners have been incorporated into the
More news about: Stellaromics
Feb 19, 2026, 07:00 ET Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update
approved for any indication in any jurisdiction.About INS1202INS1202 is an investigational adeno-associated virus (AAV9) short hairpin RNA (shRNA) construct targeting the human superoxide dismutase type 1 (SOD1) gene. Insmed is developing INS1202 as a potential treatment for patients with
More news about: Insmed Incorporated
Feb 18, 2026, 17:00 ET The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
DIEGO, Feb. 18, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the final results from the
More news about: Avidity Biosciences, Inc.
Feb 18, 2026, 11:00 ET Automotive Refrigerator Market Set for Growth Driven by Rising Demand for In-Vehicle Comfort, Electrification Trends, and Expansion of Long-Distance Mobility - Market Research Intellect
Therapeutics), Type II (Biologics and Monoclonal Antibodies), Type III (Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare Disease Therapeutics, Cell and Gene Therapy Platforms, Respiratory and Immunology
More news about: Market Research Intellect
Feb 18, 2026, 10:45 ET Cybersecurity Software Market Driven by Escalating Cyber Threats, Rapid Digital Transformation, and Expanding Enterprise Security Investments - Market Research Intellect
Therapeutics), Type II (Biologics and Monoclonal Antibodies), Type III (Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare Disease Therapeutics, Cell and Gene Therapy Platforms, Respiratory and Immunology
More news about: Market Research Intellect
Feb 18, 2026, 10:01 ET Stem Cell Therapy Market to Reach USD 45.2B by 2036 (8.4% CAGR) | U.S., Germany & Japan Lead Growth | Mesenchymal Stem Cells Hold 45% Share -- Future Market Insights
reflecting the broader push to compress development timelines with advanced modeling.Novartis and Avidity (Oct 2025): agreement for a major RNA-therapeutics acquisition expected to close in the first half of 2026 (subject to conditions), illustrating how large players are strengthening late-stage
More news about: Future Market Insights
Feb 18, 2026, 10:01 ET Autogenous Vaccines Market to Reach US$ 451.5 Million by 2033; Expands Amid Rising Livestock Health Needs and Precision Disease Control - Persistence Market Research
2032Global Flu RNA Vaccines Market by Vaccine Type (Non‑replicating mRNA, Self‑replicating mRNA, Dendritic cell mRNA, Others), by Application (Hospitals, Vaccination
More news about: Persistence Market Research Pvt. Ltd.
Feb 18, 2026, 09:05 ET NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.About ALSAmyotrophic lateral sclerosis ("ALS") is an incurable
More news about: NeuroSense
Feb 18, 2026, 07:45 ET Singular Genomics Launches G4X™ in the U.S., Delivering Industry-Leading Throughput for In Situ Multiomics, Targets Translational and Clinical Applications
The G4X platform enables simultaneous analysis of 500-plex RNA, 18-plex protein and fH&E at subcellular resolution from clinically relevant FFPE sample types at an unprecedented scale of 128 samples and 40cm2
More news about: Singular Genomics
Feb 17, 2026, 10:55 ET Database Management System (DBMS) Market Driven by Cloud Adoption, Big Data Analytics, and Rising Enterprise Digital Transformation at a CAGR of 5.5% : - Market Research Intellect
Therapeutics), Type II (Biologics and Monoclonal Antibodies), Type III (Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare Disease Therapeutics, Cell and Gene Therapy Platforms, Respiratory and Immunology
More news about: Market Research Intellect